Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: June 30, 2022 Report Code: GDGMDHC22225IDB-ST

Select Item

Risk factors of Human Papillomavirus (HPV) Associated Cancer includes smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation.

The Human Papillomavirus (HPV) Associated Cancer pipeline drugs market research report provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer (Oncology) and features dormant and discontinued projects.

HPV Associated Cancer Pipeline Drugs Market by Key Targets

Some of the key targets of the HPV Associated Cancer pipeline drugs market are Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Programmed Cell Death 1 Ligand 1, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Minor Capsid Protein L2, Transforming Growth Factor Beta ), Cells Expressing Human Papillomavirus Protein E6, Cells Expressing Human Papillomavirus Type 16 Protein E6, Envelope Glycoprotein D, and Interleukin 12.

HPV Associated Cancer Pipeline Drugs Market, by Targets

HPV Associated Cancer Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanism of Actions in the HPV Associated Cancer Pipeline Drugs Market

Some of the key mechanism of actions of the HPV Associated Cancer pipeline drugs market are Human Papillomavirus Protein E6 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Protein E7 Inhibitor, Transforming Growth Factor Beta Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Human Papillomavirus Type 16 Protein E6, Interleukin 12 Receptor Agonist, Adenosine Receptor A2a Antagonist, and CD3 Agonist.

HPV Associated Cancer Pipeline Drugs Market, by Mechanism of Actions

HPV Associated Cancer Pipeline Drugs Market, by Mechanism of Actions

For more mechanism of action insights, download a free report sample

Key Routes of Administration in the HPV Associated Cancer Pipeline Drugs Market

The key routes of administration in the HPV Associated Cancer pipeline drugs market are intravenous, intramuscular, parenteral, subcutaneous, oral, intradermal, intratumor, topical, vaginal, and inhalational.

HPV Associated Cancer Pipeline Drugs Market, by Routes of Administration

HPV Associated Cancer Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the HPV Associated Cancer Pipeline Drugs Market

The key molecule types in the HPV Associated Cancer pipeline drugs market are subunit vaccine, recombinant vector vaccine, DNA vaccine, small molecule, monoclonal antibody, cell therapy, gene-modified cell therapy, vaccine, fusion protein, and mRNA vaccine.

HPV Associated Cancer Pipeline Drugs Market, by Molecule Types

HPV Associated Cancer Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the HPV Associated Cancer Pipeline Drugs Market

Some of the key companies in the HPV Associated Cancer pipeline drugs market are Beijing Kangleweishi Biotechnology Co Ltd, Genexine Inc, Merck KGaA, Apimeds Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, eTheRNA Immunotherapies NV, Hookipa Pharma Inc, ISA Pharmaceuticals BV, and Theravectys SA.

HPV Associated Cancer Pipeline Drugs Market, by Companies

HPV Associated Cancer Pipeline Drugs Market, by Companies

To know more about the companies, download a free report sample

HPV Associated Cancer Pipeline Drugs Market Report Overview

Key Targets Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Programmed Cell Death 1 Ligand 1, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Minor Capsid Protein L2, Transforming Growth Factor Beta ), Cells Expressing Human Papillomavirus Protein E6, Cells Expressing Human Papillomavirus Type 16 Protein E6, Envelope Glycoprotein D, and Interleukin 12
Key Mechanism of Actions Human Papillomavirus Protein E6 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Protein E7 Inhibitor, Transforming Growth Factor Beta Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Human Papillomavirus Type 16 Protein E6, Interleukin 12 Receptor Agonist, Adenosine Receptor A2a Antagonist, and CD3 Agonist
Key Routes of Administration Intravenous, Intramuscular, Parenteral, Subcutaneous, Oral, Intradermal, Intratumor, Topical, Vaginal, and Inhalational
Key Molecule Types Subunit Vaccine, Recombinant Vector Vaccine, DNA Vaccine, Small Molecule, Monoclonal Antibody, Cell Therapy, Gene-Modified Cell Therapy, Vaccine, Fusion Protein, and mRNA Vaccine
Key Companies Beijing Kangleweishi Biotechnology Co Ltd, Genexine Inc, Merck KGaA, Apimeds Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, eTheRNA Immunotherapies NV, Hookipa Pharma Inc, ISA Pharmaceuticals BV, and Theravectys SA

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).
  • Reviews of pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews of key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Abivax SA
Anteris Technologies Ltd
Apimeds Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Auro Vaccines LLC
Avalia Immunotherapies Ltd
Avidea Technologies Inc
Beijing Kangle Guardian Biotechnology Co Ltd
Beijing Kangleweishi Biotechnology Co Ltd
BioMed Valley Discoveries Inc
Biond Biologics Ltd
BioNTech SE
Blue Sky Immunotherapies GmbH
Bristol-Myers Squibb Co
Cellid Co Ltd
Chain Biotechnology Ltd
Chengdu Institute of Biological Products Co Ltd
Corvus Pharmaceuticals Inc
Cue Biopharma Inc
Cullinan Oncology Inc
Elicio Therapeutics Inc
eTheRNA Immunotherapies NV
EyeGene Inc
Genexine Inc
Gilead Sciences Inc
GSK plc
HaloVax
Hookipa Pharma Inc
iBio Inc
ImmunityBio Inc
Immunomic Therapeutics Inc
IMV Inc
Innovene
Inovio Pharmaceuticals Inc
Inthera Bioscience AG
ISA Pharmaceuticals BV
KinoPharma Inc
Kovina Therapeutics Inc
Merck & Co Inc
Merck KGaA
Myrio Therapeutics Pty Ltd
NexImmune Inc
Nykode Therapeutics ASA
OncoNano Medicine Inc
Onconova Therapeutics Inc
Oxford Vacmedix UK Ltd
Papivax LLC
Pathovax LLC
Pattern Pharma Inc
PDS Biotechnology Corp
Posvax Co Ltd
Precigen Inc
Privo Technologies Inc
Rafjik Inc
Repertoire Immune Medicines Inc
Rottapharm Biotech Srl
Rubius Therapeutics Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Bovax Biotechnology Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shantha Biotechnics Pvt Ltd
Shuttle Pharmaceuticals Inc
Sirnaomics Ltd
Stemirna Therapeutics Ltd
Symvivo Inc
TCR Cure Biopharma Technology Co Ltd
Tessa Therapeutics Ltd
Theravectys SA
Toragen Inc
Touchlight Genetics Ltd
Transcenta Holding Ltd
Transgene SA
Turnstone Biologics Inc
UbiVac LLC
Vaccitech Plc
Vault Pharma Inc
Vectorite Biomedical Inc
ViciniVax BV
Vir Biotechnology Inc
Virion Therapeutics LLC
Virometix AG
Vittail Ltd
VLP The Vaccines Company SL
Voltron Therapeutics Inc
West Lake Biomedical Technology (Hangzhou) Co Ltd
Xiamen Innovax Biotech Co Ltd
Zhejiang Borui Biopharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Human Papillomavirus (HPV) Associated Cancer – Overview

Human Papillomavirus (HPV) Associated Cancer – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Human Papillomavirus (HPV) Associated Cancer – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Human Papillomavirus (HPV) Associated Cancer – Companies Involved in Therapeutics Development

Human Papillomavirus (HPV) Associated Cancer – Drug Profiles

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects

Human Papillomavirus (HPV) Associated Cancer – Discontinued Products

Human Papillomavirus (HPV) Associated Cancer – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Frequently asked questions

  • What are the key targets of the HPV Associated Cancer pipeline drugs market?

    Some of the key targets of the HPV Associated Cancer pipeline drugs market are Human Papillomavirus Protein E7, Human Papillomavirus Protein E6, Programmed Cell Death 1 Ligand 1, Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Minor Capsid Protein L2, Transforming Growth Factor Beta ), Cells Expressing Human Papillomavirus Protein E6, Cells Expressing Human Papillomavirus Type 16 Protein E6, Envelope Glycoprotein D, and Interleukin 12. 

  • What are the key mechanism of actions of the HPV Associated Cancer pipeline drugs market?

    Some of the key mechanism of actions of the HPV Associated Cancer pipeline drugs market are Human Papillomavirus Protein E6 Inhibitor, Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E7, Human Papillomavirus Protein E7 Inhibitor, Transforming Growth Factor Beta Inhibitor, Cytotoxic To Cells Expressing Human Papillomavirus Protein E6, Cytotoxic To Cells Expressing Human Papillomavirus Type 16 Protein E6, Interleukin 12 Receptor Agonist, Adenosine Receptor A2a Antagonist, and CD3 Agonist.

  • What are the key routes of administration in the HPV Associated Cancer pipeline drugs market?

    The key routes of administration in the HPV Associated Cancer pipeline drugs market are intravenous, intramuscular, parenteral, subcutaneous, oral, intradermal, intratumor, topical, vaginal, and inhalational.

  • What are the key molecule types in the HPV Associated Cancer pipeline drugs market?

    The key molecule types in the HPV Associated Cancer pipeline drugs market are subunit vaccine, recombinant vector vaccine, DNA vaccine, small molecule, monoclonal antibody, cell therapy, gene-modified cell therapy, vaccine, fusion protein, and mRNA vaccine.

  • Which are the key companies in the HPV Associated Cancer pipeline drugs market?

    Some of the key companies in the HPV Associated Cancer pipeline drugs market are Beijing Kangleweishi Biotechnology Co Ltd, Genexine Inc, Merck KGaA, Apimeds Inc, AstraZeneca Plc, Bristol-Myers Squibb Co, eTheRNA Immunotherapies NV, Hookipa Pharma Inc, ISA Pharmaceuticals BV, and Theravectys SA.

Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
Net Present Value Model: Sarepta Therapeutics Inc's Patidistrogene bexoparvovec
$500 | November 2023
Pharmaceuticals
New
Net Present Value Model: Eli Lilly and Co's Insulin efsitora…
$500 | November 2023
Pharmaceuticals
New
Net Present Value Model: Inmune Bio Inc's INKmune
$500 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more